← Back to Search

Other

HH2710 for Tumors

Phase 1 & 2
Waitlist Available
Research Sponsored by Haihe Biopharma Co., Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up c1d1,pre-dose,15min,30min,1h,2h,3h,4h,6h,8h,12h;c1d2, pre-dose and 24h; c1d7,c1d10, pre-dose.c1d15 at pre-dose,15min,30min,1h,2h,3h,4h,6h,8h,12h, c1d16 pre-dose and 24h,c1d22 pre-dose,and c2d1,c3d1,c5d1,c7d1,c9d1 pre-dose.
Awards & highlights
No Placebo-Only Group

Summary

This trial tests HH2710, a new drug for patients with advanced tumors. It works by blocking proteins that help cancer cells grow, potentially slowing or stopping the cancer.

Eligible Conditions
  • Advanced Tumors
  • Erdheim-Chester Disease
  • Melanoma
  • Non-Small Cell Lung Cancer
  • RAS/RAF/MEK/ERK Mutated Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~c1d1,pre-dose,15min,30min,1h,2h,3h,4h,6h,8h,12h;c1d2, pre-dose and 24h; c1d7,c1d10, pre-dose.c1d15 at pre-dose,15min,30min,1h,2h,3h,4h,6h,8h,12h, c1d16 pre-dose and 24h,c1d22 pre-dose,and c2d1,c3d1,c5d1,c7d1,c9d1 pre-dose.
This trial's timeline: 3 weeks for screening, Varies for treatment, and c1d1,pre-dose,15min,30min,1h,2h,3h,4h,6h,8h,12h;c1d2, pre-dose and 24h; c1d7,c1d10, pre-dose.c1d15 at pre-dose,15min,30min,1h,2h,3h,4h,6h,8h,12h, c1d16 pre-dose and 24h,c1d22 pre-dose,and c2d1,c3d1,c5d1,c7d1,c9d1 pre-dose. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
MTD (Maximum Tolerated Dose)
Number of Participants Who Experienced DLT (Dose Limiting Toxicities)
Heart rate
Secondary study objectives
Pharmacokinetic Measures - Apparent Clearance (CL/F)
Pharmacokinetic Measures - Apparent Volume of Distribution (Vz/F)
Pharmacokinetic Measures - Peak Plasma Concentration (Cmax)
+4 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Dose escalation study of HH2710Experimental Treatment1 Intervention
to determine the MTD of HH2710 and/or Recommended Phase II dose (RP2D).

Find a Location

Who is running the clinical trial?

Haihe Biopharma Co., Ltd.Lead Sponsor
16 Previous Clinical Trials
1,890 Total Patients Enrolled
~6 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top